Intelligent Bio Solutions ( (INBS) ) just unveiled an announcement.
Intelligent Bio Solutions Inc. announced the successful completion of in-clinic testing for their sweat-based drug testing method, marking a significant step towards FDA 510(k) submission. The testing included pharmacokinetic and usability studies across three sites with 135 subjects, demonstrating the potential of the non-invasive technology to provide reliable drug screening results. With this phase complete, the company is set to analyze data and aim for FDA clearance by the end of the fourth quarter of 2024, potentially revolutionizing drug screening for workplaces and government agencies.
For an in-depth examination of INBS stock, go to TipRanks’ Stock Analysis page.
